Common targets include tumor necrosis factor-alpha (TNF-α) [39], interleukin-6 (IL-6) receptors [40], and Janus kinases (JAKs) [41], which have led to the development of biologics and small molecule inhibitors that have significantly transformed RA management. The gene discussed is TNF; the disease is rheumatoid arthritis.